Terms: = Pancreatic cancer AND SMAD4, JIP, Q13485, 4089, ENSG00000141646, MADH4, DPC4 AND Prognosis
161 results:
1. Undifferentiated Carcinoma with Osteoclast-like Giant Cells of the Pancreas: Molecular Genetic Analysis of 13 Cases.
Hrudka J; Kalinová M; Ciprová V; Moravcová J; Dvořák R; Matěj R
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542259
[TBL] [Abstract] [Full Text] [Related]
2. Impact of intratumoral microbiome on tumor immunity and prognosis in human pancreatic ductal adenocarcinoma.
Abe S; Masuda A; Matsumoto T; Inoue J; Toyama H; Sakai A; Kobayashi T; Tanaka T; Tsujimae M; Yamakawa K; Gonda M; Masuda S; Uemura H; Kohashi S; Inomata N; Nagao K; Harada Y; Miki M; Irie Y; Juri N; Ko T; Yokotani Y; Oka Y; Ota S; Kanzawa M; Itoh T; Imai T; Fukumoto T; Hara E; Kodama Y
J Gastroenterol; 2024 Mar; 59(3):250-262. PubMed ID: 38242997
[TBL] [Abstract] [Full Text] [Related]
3. Successful immunotherapy with PD-1 Iinhibitor for advanced pancreatic cancer: report of two cases and review of literature.
Qiu L; Liu C; Li H
Anticancer Drugs; 2024 Mar; 35(3):263-270. PubMed ID: 38194502
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic Value and the Immune Microenvironment-associated Role of
Song Y; Wang Y; Yu T; He Y; Wang C; Wang F; Zhou Y
Anticancer Res; 2023 Dec; 43(12):5393-5408. PubMed ID: 38030175
[TBL] [Abstract] [Full Text] [Related]
5. High overall copy number variation burden by genome-wide methylation profiling holds negative prognostic value in surgically treated pancreatic ductal adenocarcinoma.
Detlefsen S; Boldt HB; Burton M; Thomsen MM; Rasmussen LG; Ørbeck SV; Pfeiffer P; Mortensen MB; de Stricker K
Hum Pathol; 2023 Dec; 142():68-80. PubMed ID: 37977512
[TBL] [Abstract] [Full Text] [Related]
6. AKT and mTOR expression in human pancreatic ductal adenocarcinoma. Relevance for tumor biology.
Handra-Luca A
Pathol Res Pract; 2023 Nov; 251():154878. PubMed ID: 37890271
[TBL] [Abstract] [Full Text] [Related]
7. The Mutation Portraits of Oncogenes and Tumor Supressor Genes in Predicting the Overall Survival in pancreatic cancer: A Bayesian Network Meta-Analysis.
Aryanti C; Uwuratuw JA; Labeda I; Raharjo W; Lusikooy RE; Rauf MA; Mappincara A; Sampetoding S; Kusuma MI; Syarifuddin E
Asian Pac J Cancer Prev; 2023 Aug; 24(8):2895-2902. PubMed ID: 37642079
[TBL] [Abstract] [Full Text] [Related]
8. Impact of smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy.
Kamata K; Takenaka M; Nishida N; Hara A; Otsuka Y; Tanaka H; Omoto S; Minaga K; Yamao K; Chiba Y; Sakai K; Nishio K; Watanabe T; Kudo M
Int J Clin Oncol; 2023 Nov; 28(11):1511-1519. PubMed ID: 37596505
[TBL] [Abstract] [Full Text] [Related]
9. A comprehensive analysis of tumor-stromal collagen in relation to pathological, molecular, and immune characteristics and patient survival in pancreatic ductal adenocarcinoma.
Ashina S; Masuda A; Yamakawa K; Hamada T; Tsujimae M; Tanaka T; Toyama H; Sofue K; Shiomi H; Sakai A; Kobayashi T; Abe S; Gonda M; Masuda S; Inomata N; Uemura H; Kohashi S; Nagao K; Harada Y; Miki M; Juri N; Irie Y; Kanzawa M; Itoh T; Inoue J; Imai T; Fukumoto T; Kodama Y
J Gastroenterol; 2023 Oct; 58(10):1055-1067. PubMed ID: 37477731
[TBL] [Abstract] [Full Text] [Related]
10. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type pancreatic cancer.
Singh H; Keller RB; Kapner KS; Dilly J; Raghavan S; Yuan C; Cohen EF; Tolstorukov M; Andrews E; Brais LK; da Silva A; Perez K; Rubinson DA; Surana R; Giannakis M; Ng K; Clancy TE; Yurgelun MB; Schlechter BL; Clark JW; Shapiro GI; Rosenthal MH; Hornick JL; Nardi V; Li YY; Gupta H; Cherniack AD; Meyerson M; Cleary JM; Nowak JA; Wolpin BM; Aguirre AJ
Clin Cancer Res; 2023 Nov; 29(22):4627-4643. PubMed ID: 37463056
[TBL] [Abstract] [Full Text] [Related]
11. Drosophila Screening Identifies Dual Inhibition of MEK and AURKB as an Effective Therapy for pancreatic Ductal Adenocarcinoma.
Sekiya S; Fukuda J; Yamamura R; Ooshio T; Satoh Y; Kosuge S; Sato R; Hatanaka KC; Hatanaka Y; Mitsuhashi T; Nakamura T; Matsuno Y; Hirano S; Sonoshita M
Cancer Res; 2023 Aug; 83(16):2704-2715. PubMed ID: 37378549
[TBL] [Abstract] [Full Text] [Related]
12. Clinical and Genomic Characterization of pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells.
Simbolo M; Silvestris N; Malleo G; Mafficini A; Maggino L; Cocomazzi A; Veghini L; Mombello A; Pezzini F; Sereni E; Martelli FM; Gkountakos A; Ciaparrone C; Piredda ML; Ingravallo G; Paolino G; Nappo F; Rapposelli IG; Frassinetti L; Saragoni L; Lonardi S; Pea A; Paiella S; Fassan M; Brunetti O; Cingarlini S; Salvia R; Milella M; Corbo V; Lawlor RT; Scarpa A; Luchini C
Mod Pathol; 2023 Sep; 36(9):100251. PubMed ID: 37355152
[TBL] [Abstract] [Full Text] [Related]
13. Cuproptosis-related lncRNAs are correlated with tumour metabolism and immune microenvironment and predict prognosis in pancreatic cancer patients.
Wang Y; Ge W; Xue S; Cui J; Zhang X; Mao T; Xu H; Li S; Ma J; Yue M; Shentu D; Wang L
IET Syst Biol; 2023 Aug; 17(4):174-186. PubMed ID: 37341253
[TBL] [Abstract] [Full Text] [Related]
14. Association of Sarcopenia with a Poor prognosis and Decreased Tumor-Infiltrating CD8-Positive T Cells in pancreatic Ductal Adenocarcinoma: A Retrospective Analysis.
Masuda S; Yamakawa K; Masuda A; Toyama H; Sofue K; Nanno Y; Komatsu S; Omiya S; Sakai A; Kobayashi T; Tanaka T; Tsujimae M; Ashina S; Gonda M; Abe S; Uemura H; Kohashi S; Inomata N; Nagao K; Harada Y; Miki M; Irie Y; Juri N; Kanzawa M; Itoh T; Fukumoto T; Kodama Y
Ann Surg Oncol; 2023 Sep; 30(9):5776-5787. PubMed ID: 37191859
[TBL] [Abstract] [Full Text] [Related]
15.
Pan M; Jiang C; Zhang Z; Achacoso N; Alexeeff S; Solorzano AV; Tse P; Chung E; Sundaresan T; Suga JM; Thomas S; Habel LA
JCO Precis Oncol; 2023 May; 7():e2200570. PubMed ID: 37163715
[TBL] [Abstract] [Full Text] [Related]
16. ncRNA-mediated upregulation of
Zou W; Wang H; Wu D; Wu Y; Zhou K; Lian Y; Chang G; Feng Y; Liang J; Huang G
Front Endocrinol (Lausanne); 2023; 14():1093042. PubMed ID: 37065746
[TBL] [Abstract] [Full Text] [Related]
17. pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and smad4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.
Voutsadakis IA; Digklia A
Chin Clin Oncol; 2023 Feb; 12(1):2. PubMed ID: 36922358
[TBL] [Abstract] [Full Text] [Related]
18. Establishment and Molecular Characterization of Two Patient-Derived pancreatic Ductal Adenocarcinoma Cell Lines as Preclinical Models for Treatment Response.
Braun R; Lapshyna O; Watzelt J; Drenckhan M; Künstner A; Färber B; Hael AAM; Bolm L; Honselmann KC; Konukiewitz B; Castven D; Spielmann M; Gorantla SP; Busch H; Marquardt JU; Keck T; Wellner UF; Ungefroren H
Cells; 2023 Feb; 12(4):. PubMed ID: 36831254
[TBL] [Abstract] [Full Text] [Related]
19. Identification of methyltransferase modification genes associated with prognosis and immune features of pancreatic adenocarcinoma.
Wang W; Zhang D; Chang D; Li Y; Ren L
Mol Cell Probes; 2023 Feb; 67():101897. PubMed ID: 36740149
[TBL] [Abstract] [Full Text] [Related]
20. Modern aspects of the management of pancreatic intraductal papillary mucinous neoplasms: a narrative review.
Pavlidis ET; Sapalidis KG; Pavlidis TE
Rom J Morphol Embryol; 2022; 63(3):491-502. PubMed ID: 36588487
[TBL] [Abstract] [Full Text] [Related]
[Next]
